400-859-2883
Your location:Home >News center >Industry News

Industry News

12-052025

21 Approved ADCs Worldwide: The Ultimate …

As of 2025, a total of 21 ADC drugs have been approved globally.

21 Approved ADCs Worldwide: The Ultimate Guide (Updated 2025)
11-182023

List of FDA Approved PEGylated Drugs Up t…

History of PEGylated drugs, list of FDA approved PEGylated drugs, advantages and challenges of PEGylation.

List of FDA Approved PEGylated Drugs Up to 2025
02-102026

Monodisperse PEG in Modern Drug Developme…

Learn how monodisperse PEG improves drug precision, safety, and consistency in ADCs, peptides, and FDA-approved therapies.

Monodisperse PEG in Modern Drug Development
01-302026

2025 FDA Drug Approvals: A Landmark Year …

With 46 new drug approvals, the agency stayed right on track with its usual pace, but the real story is in what they approved.

2025 FDA Drug Approvals: A Landmark Year for Precision and Innovation
01-202026

In Vivo CAR-T Cell Therapy: Current Strat…

This article reviews in vivo CAR-T approaches, delivery vectors, clinical pipelines, and how the field is evolving beyond ex vivo CAR-T.

In Vivo CAR-T Cell Therapy: Current Strategies and Emerging Trends
12-262025

Therapeutic Advances in Hemophilia Manage…

Hemophilia is a rare, inherited bleeding disorder, most commonly affecting males, that is characterized by a deficiency in blood clotting. The two most common severe forms are hemophilia A, c…

Therapeutic Advances in Hemophilia Management
12-162025

Next-Generation Radiopharmaceuticals: Ins…

In 2018 and 2022, Novartis achieved regulatory approval for two landmark radionuclide drug conjugates (RDCs), Lutathera and Pluvicto, marking the entry of radiopharmaceuticals into a phase of…

Next-Generation Radiopharmaceuticals: Insights into the RDC Pipeline
11-212025

Long-Acting FGF21 Therapies for MASH

The FGF21 pathway offers therapeutic potential that goes beyond single-mechanism drugs in the MASH field. Long-acting engineering strategies have largely overcome the developability challenge…

Long-Acting FGF21 Therapies for MASH
11-132025

Oligonucleotide Drug Delivery: Advances a…

Learn how GalNAc, LNP, AOC, CPP, and exosome-based systems are reshaping oligonucleotide drug delivery for precise, tissue-targeted therapies.

Oligonucleotide Drug Delivery: Advances and Future Outlook
10-272025

Tetrahydrocurcumin and its Therapeutic Po…

Tetrahydrocurcumin (THC), a major color-free metabolite of curcumin formed by reducing its central double bonds, displays better bioavailability and different biological activity and molecula…

Tetrahydrocurcumin and its Therapeutic Potential